Two molecule types are available for human use, the full-length rhPTH1–84 (less studied) and the intensively researched rhPTH1–34 analog, which contains the first 34 amino-terminal amino acids of the natural PTH molecule and is approved by the FDA and EMEA for poorly controlled hypoparathyroidism as a long-term therapy. The gene discussed is PTH; the disease is hypoparathyroidism.